Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.81 |
| ▸ | HPN | P05981 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.81 |
| ▸ | VCAM1 | P19320 | 13/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Probucol SCHEMBL5143451 | 0.90 | HPN (1.00) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL4150 | 0.90 | HPN (1.00) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL4620631 | 0.88 | ALOX15 (0.95) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL8344652 | 0.88 | ALOX15 (0.95) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL6885339 | 0.87 | HPN (0.66) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL4985953 | 0.82 | HPN (0.84) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL12791592 | 0.82 | ALOX15 (0.84) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL8344272 | 0.81 | HPN (0.81) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL6361160 | 0.81 | ALOX15 (0.62) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL9506457 | 0.79 | HPN (0.79) | ALOX15HPNMAPTSIRT5VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2008-09-04 | — | — | US | disclosed |
| US-6617352-B2 | Cardiovascular disorders; antiinflammatory agents | ATHEROGENICS, INC. | 2003-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | VCAM1, ICAM1, SELL | ALOX15 237/4885HPN 900/4885MAPT 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.